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From toxoplasmosis to 
schizophrenia via nMda 
dysfunction: peptide overlap 
between Toxoplasma gondii and  
N-Methyl-d-aspartate receptors  
as a potential Mechanistic Link
Guglielmo Lucchese*
Brain Language Laboratory, Freie Universtät Berlin, Berlin, Germany
The present work aims at investigating how Toxoplasma gondii (T. gondii) infection 
may be linked to N-methyl-d-aspartate receptor (NMDAR) dysfunction in schizophrenia 
and related disorders and puts forward the hypothesis that immune responses against 
T. gondii may involve NMDARs. Indeed, the analysis of the protozoan proteome and 
NMDAR subunits for peptide commonalities shows a massive peptide overlap and 
supports the possibility that anti-T. gondii immune responses raised during active 
protozoan infection may cross-react with host NMDARs, determining disruption of 
neural circuits and cognitive deficits. In particular, the NMDA 2D subunit, which is mainly 
expressed in parvalbumin-positive interneurons, appears to be a hotspot for potential 
T. gondii-induced cross-reactive immune attacks.
Keywords: Toxoplasma gondii, N-methyl-d-aspartate receptors, nMda 2d, peptide commonality, immune cross-
reactivity, schizophrenia, parvalbumin-positive interneurons, gamma oscillations
introdUCtion
Schizophrenia is a multifaceted syndrome characterized by distinctive behavioral symptoms, cogni-
tive deficits, and a complex etiopathogenesis, which seems to involve neurodevelopmental anomalies 
and a combination of genetic and environmental factors (1, 2). Among the environmental factors, 
Toxoplasma gondii (T. gondii) is gaining increasing attention, and a causal association between the 
protozoan infection and schizophrenia has been repeatedly suggested (3–9). Over the last decades, 
studies on T. gondii antibodies (Abs) in patients with schizophrenia revealed higher levels of anti- 
T. gondii Abs in the affected persons when compared to controls (8, 10–12). Interestingly, higher 
anti-T. gondii Ab levels were also found in mothers of offspring who later developed schizophrenia 
(13) and in newborns who later were diagnosed with the disease, as compared to controls (6, 14). 
This suggests that toxoplasmosis in early life might affect neurodevelopment and contribute to later 
onset of schizophrenia. However, the molecular determinants and mechanisms by which T. gondii 
infection might contribute to the pathophysiology of the disease remain unclear.
One major pathophysiological mechanism underlying development of schizophrenia seems to 
be N-methyl-d-aspartate glutamate receptor (NMDAR) dysfunction (15–17). The NMDA model 
of schizophrenia originated from the observation that NMDA antagonists, like ketamine or 
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phencyclidine (PCP), transiently induce symptoms that mimic 
psychotic episodes (18–21). Following these initial observations, 
a large body of genetic and molecular evidence has accumulated 
in the last three decades indicating NMDA dysfunction as a 
convergence point in the development of schizophrenia (22–27). 
NMDA dysfunction not only can provide a satisfactory expla-
nation of behavioral and cognitive symptoms of schizophrenia 
but is also consistent with the neurodevelopmental aspect of the 
disease, given that early NMDA aberrations/damage can translate 
into clinical onset later in life (22, 28, 29).
In summary, the NMDA model of schizophrenia seems then 
to be the common pathway of different etiological factors and 
is characterized by an early-damage late-onset temporal pattern, 
which is consistent with findings on increased risk of schizophre-
nia after early-life T. gondii infection. It is therefore reasonable 
to hypothesize that T. gondii can affect NMDAR function and 
glutamatergic neuronal circuits.
On this basis, the present work examines the hypothesis that 
immune responses to T. gondii may relate to NMDAR dysfunction 
by way of cross-reactive mechanisms and anti-NMDAR Abs. The 
rationale is that when a pathogen has sequence/structure similarity 
with human proteins, then anti-pathogen immune responses may 
cross-react with human proteins that share sequences/structures 
with the pathogen, thus triggering autoimmunity (30, 31). Such a 
hypothesis originates form the observations that (1) anti-T. gondii 
Ab levels are, as discussed above, higher in schizophrenic patients 
(8, 10–12), thus suggesting that immune responses following 
T. gondii active infection might play a role in the association of 
the parasite with the disease and (2) NMDAR blocking Abs are 
present in subjects with schizophrenia, schizoaffective, bipolar, 
and major depressive disorders (32–37), thus suggesting a role 
of anti-NMDAR immunoreactivity in the genesis of NMDA dys-
function in schizophrenia and other neuropsychiatric disorders. 
Moreover, a direct effect of early toxoplasmosis on behavioral 
anomalies and elevation of anti-NMDAR autoantibodies was 
found in a recent study on mice (38).
In light of this immunologic context, T. gondii proteome and 
the seven NMDAR subunit proteins (NMDA 1, 2A, 2B, 2C, 2D, 
3A, and 3B) were searched for common peptides that might 
underlie immune cross-reactions between the protozoan and 
the human host. Data are reported showing that the T. gondii 
proteome and NMDAR subunits share a vast epitopic peptide 
platform that is centered on the 2D subunit and appears to be 
potentially significant to schizophrenia pathogenesis.
MetHods
The seven human NMDAR subunit aminoacidic sequence 
analyzed in this study were retrieved from the UniProt database1 
(39), and are listed with their alternative names in parentheses, 
followed by amino acids (aa) length: NMDA 1 (GluN1, NMDZ1), 
938; NMDA 2A (GluN2A, NMDE1), 1,464; NMDA 2B (GluN2B, 
NMDE2), 1,484; NMDA 2C (GluN2C, NMDE3), 1,233; NMDA 
1 www.uniprot.org.
2D (GluN2D, NMDE4), 1,336; NMDA 3A (GluN3A, NMD3A), 
1,115; and NMDA 3B (GluN3B, NMD3B), 1,043.
The protein sequence of each NMDA subunit was dissected 
into sequential hexapeptides that overlapped each other by five 
aa (for example, MSTMRL, STMRLL, TMRLLT, MRLLTL, and 
so forth). This procedure produced a library consisting of 8,578 
NMDAR subunit hexapeptides. Each NMDAR hexapeptide 
was used as a probe to search the entire T. gondii proteome for 
occurrences of the same hexapeptide using the Pir Peptide Match 
program2 (40).
Toxoplasma gondii (strain VEG, NCBI Tax ID: 432359) was 
investigated. The T. gondii proteome consists of 8,404 proteins 
(Uniprot proteome: UP000002226). The protozoan Entamoeba 
histolytica (NCBI Tax ID: 5759; 7,959 proteins; Uniprot proteome: 
UP000001926) was used as a control.
The Immune Epitope DataBase3 (IEDB) (41) was searched 
for epitopes containing (or corresponding to) NMDAR 
hexapeptide(s) shared with T. gondii and experimentally 
validated as immunopositive in humans. Details, references, and 
immunoassay type for each epitope reported in the present study 
are available at http://www.iedb.org/advancedQueryEpitope.php.
resULts
Sequence-matching analyses were carried out at the 6-mer level 
since a grouping of 5–6 aa represents the minimal immune unit 
able to induce specific Abs and to determine specific antigen–
antibody recognition (42–44).
The hexapeptide sharing between NMDAR subunits and 
T. gondii proteins and its immunological potential is quantified in 
Table 1 and detailed in Table S1 in the Supplementary Material. 
Table 1 shows that the seven NMDAR subunit proteins share a 
high number of hexapeptides with the protozoan proteome. On 
the whole, 2,215 out of the 8,578 hexapeptides composing the 
NMDAR library repeatedly occur in the protozoan proteome, 
for a total of 5,802 multiple occurrences. Theoretically, such an 
impressive level of peptide sharing equates to a vast source of 
potential cross-reactions in case of active toxoplasmosis and, 
indeed, NMDAR hexapeptides shared with the T. gondii pro-
teome are also present in immunopositive epitopes (Table 1, last 
column).
In order to define the immunologic potential of the hexapep-
tide commonality between NMDARs and T. gondii, the shared 
2,215 hexapeptides were analyzed using the IEDB, an immune 
epitope catalog resource, in search of epitopes experimentally 
validated as immunopositive in the human host, and containing 
(or corresponding to) hexapeptides shared between T. gondii 
and human NMDAR proteins. One hundred sixty out of the 
2,215 hexapeptides shared between the 7 human NMDARs and 
T. gondii were found to be disseminated through hundreds of 
IEDB epitopes that have been validated as immunopositive in 
humans. The 160 epitopic NMDAR hexapeptides and the IEDB 
epitopes are described in Tables 2 and 3, respectively.
2 http://research.bioinformatics.udel.edu/peptidematch/index.jsp.
3 www.immuneepitope.org.
taBLe 1 | N-methyl-d-aspartate receptor (nMdar) hexapeptide sharing with Toxoplasma gondii proteome.
nMdar 
subunit
total number of 
hexapeptides
Hexapeptides shared with T. gondii 
proteome
Hexapeptides shared with T. gondii 
proteome (including multiple occurrences)
Hexapeptides shared with 
T. gondii proteome and present 
in immunopositive epitopes
1 933 180 504 10
2A 1,459 254 488 16
2B 1,479 258 400 7
2C 1,228 374 947 22
2D 1,331 496 1,463 58
3A 1,110 262 977 8
3B 1,038 391 1,023 44
total: 8,578 2,215 5,802 165
3
Lucchese NMDARs vs T. gondii Peptide-Sharing
Frontiers in Psychiatry | www.frontiersin.org March 2017 | Volume 8 | Article 37
Control analyses using the protozoan E. histolytica, a human 
pathogen associated with intestinal and extraintestinal infections 
(45), highlight a lower extent of peptide sharing (Table 4), thus 
indicating that the intensity of the hexapeptide sharing between 
T. gondii and the NMDAR subunits—in particular, NMDA 
2D and 3B—is specific (Tables 1 and 2). The detailed descrip-
tion of the peptide sharing between the NMDAR subunits and 
the protozoan E. histolytica is reported in Tables S2 and S3 in 
Supplementary Material.
disCUssion
the spatiotemporal nMdar subunit 
expression May shape the potential 
Cross-reactions between T. gondii and 
nMdars
Tables  2 and 3 indicate that T. gondii active infection might 
induce immune reactions able to cross-react to different extents 
with the seven NMDAR subunits. In particular, analysis of 
Table 2 shows that epitopic hexapeptides shared with T. gondii are 
mostly allocated in the NMDA 2D, 3B, and 2C subunits (58, 44, 
and 22 epitopic hexapeptides, respectively), whereas a relatively 
lower level of hexapeptide sharing characterizes NMDA 2A, 1, 
3B, and 3A (16, 10, 8, and 7 epitopic hexapeptides, respectively).
This appears to be relevant in light of the fact that NMDARs 
consist of four subunits, two of which invariably are NMDA 1 
subunits that can associate with NMDA 2 subunits or a com-
bination of NMDA 2 and NMDA 3 subunits. Such a variable 
composition results in a large number of NMDAR subtypes, 
which present different spatiotemporal patterns of expression 
during neurodevelopment and in the young/adult life (46). 
For instance, NMDA 2B and NMDA 2D are expressed during 
embryonic development, whereas NMDA 2A and NMDA 2C 
gene expression starts after birth; NMDA 2A and NMDA 2B are 
highly expressed in the cortex and hippocampus and NMDA 2C 
in the cerebellum of adult rodents (47–52). Likewise, NMDA 3A 
and NMDA 3B genes have specific developmental patterns of 
expression (53).
Even the NMDA 1 subunit, which is a constitutive compo-
nent of all NMDARs, presents a heterogenous distribution and a 
varying immunoreactivity potential when its seven isoforms are 
analyzed (54). For example, only immune cross-reactions against 
6 out of the 10 epitopic hexapeptides present in all NMDA 1 
isoforms (Table  2)—namely, AGGIVA, EEEEED, ELEARV, 
ELLEKE, SPGSPR, and SVARAA—should be able to produce a 
diffuse immunoreactivity in the brain.
Hence, T. gondii-induced immune cross-reactions might have 
different outcomes depending on the targeted NMDAR subunit 
and might target different subunits depending on the timing of 
exposure to the protozoan. Indeed, the timing of exposure to 
T. gondii is a crucial factor in generating different specific anti-
NMDAR Abs and, consequently, different associated neurobe-
havioral disorders (38).
nMda 2d is the Main potential target of 
anti-T. gondii immune response
NMDA 2D exemplifies the potential relationship between 
toxoplasmosis-induced immunoreactivity, the spatiotemporal 
expression profile of NMDAR subunits, and different potential 
outcomes. Indeed, NMDA 2D contains 496 hexapeptides in com-
mon with the protozoan (Table  1), 58 of which are present in 
validated immunopositive epitopes (Table 1). Therefore, NMDA 
2D might be the main target of the immune cross-reactivity 
potentially associated with T. gondii infection. Studies in animals 
[(48–52) and more references therein] showed that NMDA 2D 
gene expression:
 – is high in the midbrain, the diencephalon, and the spinal cord 
before birth;
 – is abundant around birth in thalamic and hypothalamic nuclei 
and in the brainstem;
 – reaches a peak around 1 week after birth; and
 – subsequently declines and persists mainly in the hippocampal 
interneurons, most of which are somatostatin (SOM)- and 
parvalbumin (PV)-positive cells.
Translating data from animal models to the human brain, 
it is logical to presume that immune cross-reactions involving 
NMDA 2D in the fetus and the newborn can extensively occur 
throughout the brain, whereas secondary immune responses 
after early sensitivization might target hippocampal PV- and 
SOM-positive interneurons in the young/adult. Indeed, altera-
tions in the hippocampal PV- and SOM-positive interneurons 
have been repeatedly related to the hippocampal hyperactivity 
that characterizes schizophrenia (55–57).
taBLe 2 | epitopic hexapeptides shared between the seven human 
N-methyl-d-aspartate receptor (nMdar) subunit proteins and T. gondii 
proteome and present in epitopes experimentally validated as 
immunopositive in humans.a,b
nMda 1 nMda 
2a
nMda 
2B
nMda 
2C
nMda 2d nMda 
3a
nMda 
3B
AGGIVA AAAEKG AAPVAV AGVSSS AAAATA APRAAS AALARA
EEEEED aLsLit aLsLit ASPPRQ AAPPPA eeLsGi AAPAEA
ELEARV APSAAA LAVLAV FLDLPL AATAVG LLEKIA AEAEAA
ELLEKE EELETL LKtGKL GPALLL AGGAGG NFSLLL ALLPRA
GRGALQ ISLKDR LRLLRT GPGGPR AGGGGS PFSSPS ALLSSL
LVAGGI KGPPAL QEAIAQ LGPALL APGPAP PPGSRK APRLPH
RGALQN LEARVR QKEEAA LLLTSL APPAAA SELEKQ APVPAA
SPGSPR LKtGKL LLTSLF APPPPP VPSSSS ARAAPA
SVARAA LPALLV LSLRQK APRGAA ARARAR
TLASSF LRSTAS LtVatL APRPAP ARPPPP
RELDLS PALLLT AVAAAV ATLDAL
SLEARV PGGPRA AVGPPL EAPVPA
SRDSRG PPPSPC AVVARG eeLsGi
SRPSRS QASPDL GAAGRP EGSKEE
SRSISL RSVEDA GAALVL ELVVAA
SSVILL SASERP GAGEAV EQQQQQ
SFSPGG GAGGAG ERLRQA
SLASPP GAGGGA GEAPVP
SSVAEA GAGGPG GGLVAL
TAGVSS GAPAAP GLALAL
TDAPPA GASLGG GLLALG
tVatLe GGAGGG GRPPAA
GGAGGP GSALLS
GGGGSG GVAALL
GGGLGG GVLARL
GGPGGG LARAAL
GKKIDG LEHPFV
GLGLGL LERRIE
KPPPPP LGSALL
LAGGGG LLAQLG
LELLPP LLQARA
LLLLAL LQARAA
LLSGLR PEADAE
LPPPAP PGVAAL
LtVatL PPGVAA
PAAAAP PPPPQG
PAAAAT PRAPLA
PAEPPA PTGAPQ
PAPPAA QELERR
PGPGGA QQQQQQ
PLPSPA RARAAL
PPAAAA RARARA
PPPPPQ RLRQAL
PRGAAG VLSLLR
PSPPAP
PVALVL
RAAPPP
RAPAVA
RGAGGP
RGAQAL
RGPRGP
SGPAYA
SLELLP
SPPAPA
TPAAAA
tVatLe
VRPVAL
VSAQIR
aHexapeptides common to the seven isoforms of NMDA 1 are given underlined.
bThe five hexapeptides present in more than one subunit are in bold.
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nMdars vs T. gondii epitopic peptide 
overlap and the nMda Model of 
schizophrenia
The vast epitopic peptide sharing between T. gondii and the 
seven NMDAR subunits (see Tables 2 and 3) suggests that anti- 
T. gondii immune responses cross-reacting with NMDARs might 
lead to NMDAR damage and dysfunction, targeting in particular 
interneurons expressing NMDA 2D. Crucially, this hypothesis, 
which links mechanistically toxoplasmosis and schizophrenia by 
way of peptide sharing with NMDARs, is consistent with the well-
established NMDA dys/hypofunction model of schizophrenia 
(15–17). As mentioned in the Introduction, the NMDA model 
is based on the observation that NMDA antagonists, like PCP, 
Ketamine, and MK801, induce symptoms that resemble schizo-
phrenia (2, 17), and it seems to be able to provide a good account 
of some aspects of the complex symptomatology of the disease, 
including cognitive symptoms (17). Remarkably, both of these two 
fundamental aspects of the NMDA model are related to the NMDA 
2D subunit type. First, targeting NMDA 2D appears to be a major 
mechanism in the pharmacodynamics of MK801 (58), ketamine 
(59, 60), and PCP (61, 62). Second, 2D-containing NMDARs are 
typically expressed in GABAergic interneurons, where they largely 
contribute to excitatory post-synaptic potentials (49, 51, 63). 
Consequently, NMDAR dysfunction in these cells would 
translate into reduced GABAergic activity and consequent 
reduced inhibitory control of pyramidal cell activity (2, 64). The 
excitatory–inhibitory balance in cortical networks is crucial for 
generating high-frequency (gamma) oscillatory activity (65, 66), 
and it appears that the disruption of gamma-band oscillations 
(GBOs) might indeed underlie cognitive deficits in schizophrenia 
(67–70). On the one hand, GBOs are well known to be physiologi-
cally related to higher cognitive functions (71–74), on the other 
hand, they are typically altered in schizophrenic patients (75–77). 
Moreover, ketamine alters gamma oscillatory activity by targeting 
NMDA 2D (59). It appears then that NMDA 2D damage can be 
directly related to cognitive deficits in schizophrenia.
In summary, in the complex and articulated picture that 
connects PV interneurons, brain oscillation, and cognition 
[Ref. (78, 79) for review], a large body of evidence from phar-
macological, genetic, electrophysiological, and clinical research 
converges on a critical role of NMDA 2D in cognition within the 
context of the NMDA model of schizophrenia. It is likely then 
that T. gondii-induced anti-NMDA 2D cross-reactivity might, 
among other different mechanisms triggered by both genetic 
and environmental factors, play a role in contributing to NMDA 
dysfunction and GABA hypofunction, thus resulting in cortical 
circuitry disequilibrium and, potentially, in disruption of brain 
oscillation and cognitive processes.
ConCLUsion
This work presents and examines the hypothesis that the rela-
tionship between T. gondii and schizophrenia might be explained 
by way of shared peptides (as molecular determinants) and 
immune cross-reactivity (as biological mechanism) between 
T. gondii proteins and the NMDAR subunits. The high and 
taBLe 3 | immunopositive epitopes containing hexapeptides shared between the seven human N-methyl-d-aspartate receptor (nMdar) subunit 
proteins and T. gondii proteome.
iedB 
ida
epitopeb iedB 
ida
epitopeb iedB 
ida
epitopeb iedB 
ida
epitopeb iedB 
ida
epitopeb
364 aapLPPPAPd 178516 ALLPRAgaaaaaalp 243209 rvLRLLRTlrplrvi 446380 lprALLSSL 460038 tpAVGPPL
1432 aGAGGGAGGAGag 179362 QASPDLlrgllstfi 255107 apakaaAPPAAArsa 446610 miRAAPPPl 460172 vagLAVLAV
11210 eavesTVATLEd 179712 ylglevltRARAALt 260421 avGVAALLplptvva 446684 mPPPPPQGv 460179 vAPPPPPvev
16552 FLDLPL 180820 wlvhrqwFLDLPLpw 265472 ddddddepeEGSKEE 447353 rgsLARAAL 460604 VRPVALVL
16553 FLDLPLpwl 189280 slyLTVATL 275388 edEEEEEDEEEEEDe 447526 rpaLPALLV 460633 vtlasGGLVAL
16554 FLDLPLpwt 193670 aLLSGLRea 348447 pakaaAPPAAArsae 448486 sPGGPRAav 460697 wlknGAALVL
19674 gGAGGAGGaGAGGGA 193930 iiNFSLLLv 348613 papakaaAPPAAArs 448497 SPGSPRpal 463472 APPPPPppv
34978 laTAGVSSSdslvsp 194050 kliEELETL 359598 qekkeEEEEEDgieq 451566 aaaPAPPAA 463529 APRPAPvaqppaaa
46489 nvsVPSSSStplly 194088 klPPPPPQa 375698 sapakaaAPPAAArs 451598 aaPAAAAPa 463617 APVPAAaav
48720 pnvsVPSSSStplly 196338 APPPPPppp 410921 vsapakaaAPPAAAr 451603 aaPAPPAAA 465860 glsgSGPAYA
51177 QKEEAAicgqmdls 196592 KPPPPPppp 418132 fqinqdEEEEEDed 451607 aAPGPAPl 466021 gpPSPPAPvm
67823 vaytlaTAGVSSSds 198666 AEAEAAsvrm 418885 sprrSRSISL 451608 aAPPAAAAa 466282 hlwtgevsAAPPPA
68358 vesTVATLEd 199105 aeprPAEPPAw 419522 apqAPPPPPk 451658 AEAEAAvgl 466749 ipLLLTSL
69908 vlyspnvsVPSSSS 202838 atASPPRQk 420032 pvRAPAVAv 452024 aEQQQQQmy 466793 iprgpPSPPAPv
73319 yAALARAAL 210095 gLLEKIATpk 420626 kLVAGGInav 452378 ALLSSLarc 466794 iprgpPSPPAPvm
77946 LGPALLLll 217152 qlkLKTGKL 423463 prppplgrgRGAGGP 452567 aPAAAAPaa 469288 ppAPPPPPv
94735 VPSSSStpl 217651 RELDLSgqgf 423802 AAAATAdvtly 452663 apgKGPPAL 470036 rpikGAAGRPlel
103165 feetfevtaAAPVAV 219411 spaSRSISL 424158 avSSVAEAy 452666 APGPAPsql 470660 slmaelGEAPVPAsv
103645 tgGGGGSGfsnsgsg 222405 GEAPVPAsv 424351 ffGAGGAGy 452751 APPPPPkal 474124 yTDAPPAysel
113351 eaGAGGGA 224924 pAPPPPPpp 424829 GASLGGiiy 452752 APPPPPtsm 474710 AEAEAAavhga
114666 vrSRPSRSrssrser 227016 aGAGGGAGAGGAGGa 424842 gffGAGGAGy 452779 aprelGLGLGL 474785 aeAPPPPPp
115985 sTVATLEdsp 227017 AGAGGGAGAGGGAgg 426558 nlLQARAAlqtay 452781 APRGAAGl 475138 aelGEAPVP
118616 svsyddwdySLEARV 227018 AGAGGGAGGAGaggg 427326 SLELLPPp 452792 APRPAPvaq 475252 aeqepELEARVa
121117 adGKKIDG 227019 aGAGGGAGGAGGaga 433554 yTDAPPAysely 452810 APSAAAlpa 476614 avrPPAAAAak
121776 RARARARa 227020 AGAGGGAGGAGGagg 435140 grlPLPSPAl 453128 dqvgGVLARL 477189 eaPAAAATA
121811 rRARARAR 227021 aggaGAGGAGaggag 435175 grSSVILLty 454126 gLAVLAVvv 477192 eAPPPPPpp
122052 ykhadGKKIDGrrvl 227023 aggaGAGGGAgagga 435395 krQEAIAQnr 454159 GLLALGdymnv 477741 eLGSALLSl
127989 ggaGAGGGAgagg 227024 aggaGAGGGAGGAGG 437234 fELLEKEvgl 454273 GPGGPRnl 479011 gveGAPAAP
132330 GGGLGGtrrg 227025 aggGAGGAGAGGGAg 437708 gPPPPPQGgrpp 454675 ikGAAGRPlel 482100 lqkLKTGKL
132548 prrlGGGLGG 227188 gaGAGGGAGGAGagg 437719 gptslgGGAGGPll 455937 lAAPPPApa 482881 paaAPPAAA
132613 rlGGGLGGtr 227189 GAGGAGAGGGAGGAG 438549 kEQQQQQmw 455970 lAPPPPPaa 483053 qeAPPPPPp
138044 SRDSRGkpgy 227204 ggGAGGAGAGGGAgg 438691 klqELEARV 456697 lsrlPALLLTg 486281 spaSRSISLl
142502 aAGGGGStdnlsy 235218 lGVAALLfgfpiffd 439841 refPEADAEkl 457321 paAAAATAl 487382 tevAPPPPP
144908 iepRGAQAL 236707 aeLRSTASll 440445 SELEKQdnsw 457322 PAAAAPaaa 492366 iRAAPPPlfll
146892 epeAEAEAAagpgp 239263 AATAVGggflll 441412 vLLAQLGpqpg 457324 paaPAAAAPgy 492772 krGLALALf
150802 iRAAPPPlf 239392 alLAGGGGppak 442395 amPPPPPQGv 457338 papARAAPA 493404 mrpGPALLLlgv
156427 qqgrQQQQQQQgqqg 239445 aprelglGLGLGL 442558 appERLRQAL 457425 PPGVAALsi 495305 srTPAAAAam
161826 aegGRPPAA 239460 aprpaAAAATAl 442568 APRAAStesl 457922 rARPPPPstl 504497 APGPAPtrc
162831 LEHPFVssi 239463 APRPAPvaqppa 442615 APRLPHsvtc 458285 rpaGPALLL 504498 APGPAPtrcl
169260 maiakaAAAEKGvpl 239473 aprtPGPGGArl 442702 apsSPGSPRpal 458546 rpyLGPALL 505654 gpgifPPPPPQp
176712 VSAQIRknf 239607 eestgLLSGLRiw 443010 AVVARGttilak 458547 rpyLGPALLL 505667 gPPPPQGkp
176870 AEAEAAavhgarf 240452 SPPAPAgsratl 444271 glaAGGIVAv 458577 RSVEDAqaw 507174 miRAAPPPlf
176959 agytpatpAAPAEAa 240535 stAPPPPPllle 444325 gLVAGGIiga 459541 sprpaLPALLV 507502 pgaRGPRGPp
177000 eaqkaakPAAAATAt 240571 tgggGGGGSGgtrm 444514 grlPLPSPAley 459542 sprPFSSPSm 507608 qgPPPPQGkpq
177124 kaakPAAAATAtata 240573 tkeAVAAAVaav 445222 iRAAPPPlfl 459704 sTLASSFk 509894 LPPPAPaev
177139 kPAAAATAtataavg 242669 ilgmlrvLRLLRTlr 446022 ktlLLTSLF 459875 tgAPGPAPp 510025 ndAPRAASi
aImmunopositive epitopes containing hexapeptides shared between T. gondii and NMDAR subunits are listed according to IEDB ID number. Only epitopes ≤15 aa are reported. 
Details and references are available at www.immuneepitope.org/.
bPeptide sequences shared between NMDAR subunit proteins and T. gondii proteome are given in capital letters.
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specific peptide commonality with the NMDARs shown by T. 
gondii, as compared to the control, supports the possibility that 
the infection might induce anti-NMDAR immune responses in 
the human host through cross-reactivity (Table 1) and more so 
in light of the epitopic nature of many of the shared peptides 
(Tables  2 and 3). Such a hypothesis is consistent, on the one 
hand, with previous studies describing the potential neuropsy-
chiatric relevance of the vast peptide commonality existing 
between infectious agents and the human host (80–82) and, on 
the other hand, with the well-established NMDA dysfunction 
model of schizophrenia. Hence, a possible scenario unfolds, 
where the differential spatiotemporal patterns of expres-
sion of the NMDAR subunits might generate the diversity of 
neuropathological outcomes. In this regard, immune attacks 
on NMDA 2D, a main potential target of T. gondii-induced 
cross-reactions, may represent a mechanistic link between 
T. gondii infection and NMDAR dysfunction in neuropsychiatric 
disorders.
taBLe 4 | N-methyl-d-aspartate receptor (nMdar) hexapeptide sharing with Entamoeba histolytica proteome.
nMdar 
subunit
total number of 
hexapeptides
Hexapeptides shared 
with E. histolytica 
proteome
Hexapeptides shared with E. histolytica proteome 
(including multiple occurrences)
Hexapeptides shared with E. histolytica 
proteome and present in immunopositive 
epitopes
1 933 100 240 13
2A 1,459 134 227 10
2B 1,479 160 241 9
2C 1,228 92 141 5
2D 1,331 109 192 15
3A 1,110 101 211 3
3B 1,038 86 142 10
total: 8,578 782 1,394 65
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In summary, immune cross-reactions with NMDARs follow-
ing T. gondii infection might be one of the factors contributing to 
the pathophysiology of schizophrenia and associated disorders, 
and NMDAR subunit composition could relate to the timing 
and the targets of the neuropathologic sequela of the exposure 
to T. gondii. The hypothesis presented here might help to address 
aspects of the complex and multifactorial etiopathogenesis of 
schizophrenia in future clinical and basic research.
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